Skip to main content
Helmholtz Munich logoHelmholtz Munich logoHelmholtz Munich logoHelmholtz Munich logoHelmholtz Munich logo
Banner Research Area GPPAD
Helmholtz Munich | ©Andreas Pfohl, NOZY Films GmbH

Global Platform for the Prevention of Autoimmune Diabetes (GPPAD)

GPPAD is an European platform to identify infants with an elevated genetic risk of developing type 1 diabetes, and to perform primary prevention trials aiming to reduce the incidence of islet autoimmunity and type 1 diabetes in children.

GPPAD is an European platform to identify infants with an elevated genetic risk of developing type 1 diabetes, and to perform primary prevention trials aiming to reduce the incidence of islet autoimmunity and type 1 diabetes in children.

Director GPPADWebsite Institute

GPPAD Studies

Logo Freder1k ohne Untertitel
Newborn screening for genetic predisposition of type 1 diabetes using a polygenic 51 SNP risk score
2024_Avant1a_Logo_klein
Primary prevention study to determine whether vaccinating children with an elevated genetic risk for type 1 diabetes against SARS-CoV influences immune development, beta-cell function, and the risk of islet autoimmunity
SINT1A Logo
Primary intervention study to determine whether daily administration of B. infantis EVC001 until age 12 months to children with elevated genetic risk for type 1 diabetes reduces the cumulative incidence of beta-cell autoantibodies in childhood
Primary intervention study to determine whether daily administration of oral insulin to children with elevated genetic risk for type 1 diabetes reduces the cumulative incidence of beta-cell autoantibodies and diabetes in childhood.
HH_GPPAD_MAP_Europe_EN
Helmholtz Munich - Johannes Schreiber

The GPPAD research sites are located in Belgium (Leuven), Germany (Dresden, Hanover, Munich), Poland (Warsaw), Sweden (Malmo) and the United Kingdom (Birmingham, Cambridge, Newcastle, Oxford).

Read more about GPPAD

The GPPAD Coordination Center is located at Helmholtz Munich with the following structure and organizational departments:

Regulatory affairs

Responsible for regulatory and ethical committee submissions, study documents and tools, TMF maintenance, management of monitoring and audits, central data review and data cleaning, coordination of external vendors, SOPs and IMP management.

Contact Stefanie Arnolds

Biometrics & statistics

Responsible for trial design, interim reports and analysis. Oversees recruitment, and development of endpoints.

Contact Andreas Weiß

Database & biosample management

Responsible for database and data integrity, logistics, LIMS, data and query management.

Contact Florian Haupt

Pharmacy & IMP

Oversees IMP/ study product manufactory activities.
Contact with pharmacy and manufacturers.

Contact Peter Achenbach

Central laboratory

Responsible for SOP sample collection/ processing/storage, laboratory measurements and logistics, result reporting, biobank and storage management.
Contact to central laboratories and central biobank.

Contact Marlon Scholz

Medical oversight, safety & study outcomes

Responsible for medical monitoring of safety data and study outcomes. Overall responsibility for successful study conduct generating reliable data of scientific value.

Contact Anette-G. Ziegler

Central office

Responsible for general communication, PR activities, homepage design and content, event management, finances and contracts.

Contact Melanie Gündert

Contact

Anette G. Ziegler_84

Univ.-Prof. Dr. med. Anette-Gabriele Ziegler

Institute Director, Chair of Diabetes and Gestational Diabetes, Klinikum rechts der Isar and Technical University of Munich, Director of the Global Platform for the Prevention of Autoimmune Diabetes (GPPAD)

Heidemannstraße 1, 80939 München